The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes

Vandana S. Raman, MD; Kimberly J. Mason, RN; Luisa M. Rodriguez, MD; Krishnavathana Hassan, MD; Xiaoying Yu, MS; Kisa Bomgaars, MD; Rubina A. Heptulla, MD

Disclosures

Diabetes Care. 2010;33(6):1294-1296. 

In This Article

Conclusions

Our study demonstrates reduction in postprandial glucose after exenatide injection in adolescents with type 1 diabetes. These effects were associated with delayed gastric emptying, and the results are consistent with published studies in adults.[13,14] However, as opposed to previous reports, glucagon suppression was not noted with exenatide, which could be because of the small sample size of our study.

Both exenatide doses were comparable in reducing postprandial glucose excursions, and hence the lower dose could be tested as an initial dose and titrated to response and tolerability in a larger cohort of subjects. Pharmacokinetic data are included in the online appendix (available at http://care.diabetesjournals.org/cgi/content/full/dc09-1959/DC1), and data are comparable to adults. Caution must be exercised if blood glucose is low to omit exenatide or use lowered insulin and/or exenatide dose.

In conclusion, adjunctive exenatide therapy has therapeutic potential in adolescents with type 1 diabetes. Further studies are ongoing using exenatide for a 4-month period.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....